Litcius/Paper detail

Cardiac computed tomography-derived extracellular volume fraction in late anthracycline-induced cardiotoxicity

Koichi Egashira, Daisuke Sueta, Mai Tomiguchi, Masafumi Kidoh, Seitaro Oda, Hiroki Usuku, Kaori Hidaka, Lisa Goto‐Yamaguchi, Aiko Sueta, Takashi Komorita, Masafumi Takae, Fumi Oike, Koichiro Fujisue, Eiichiro Yamamoto, Shinsuke Hanatani, Seiji Takashio, Yuichiro Arima, Satoshi Araki, Koichi Kaikita, Kenichi Matsushita, Yutaka Yamamoto, Toshinori Hirai, Kenichi Tsujita

2021IJC Heart & Vasculature14 citationsDOIOpen Access PDF

Abstract

Cardiotoxicity in the late phase after anthracycline drugs administration remains to be defined. Of the 44 patients who received anthracycline treatment, 7 were found to have cancer therapeutics-related cardiac dysfunction (CTRCD). The global longitudinal strain determined by echocardiography and myocardial extracellular volume fraction (ECV) determined by cardiac computed tomography (CCT) of the CTRCD(+) group were significantly higher than those of the control group and CTRCD(-) group, whereas there were no significant differences between the control and CTRCD(-) groups. Our findings indicated that CCT may be a tool comparable to echocardiography, indicating the effective evaluation of CTRCD by CCT.

Topics & Concepts

CardiotoxicityMedicineAnthracyclineCardiologyEjection fractionCancerInternal medicineChemotherapyBreast cancerHeart failureChemotherapy-induced cardiotoxicity and mitigationCardiac Imaging and DiagnosticsPolymer Nanocomposite Synthesis and Irradiation
Cardiac computed tomography-derived extracellular volume fraction in late anthracycline-induced cardiotoxicity | Litcius